Kaerus Bioscience’s BK channel openers for Fragile X syndrome are advancing through Phase 1 trials, offering hope for new treatments with FRAXA’s continued support.
Read moreBriault, Sylvain
Sylvain Briault, PhD, Team Leader at CNRS Orleans, researches neurodevelopmental disorders and received a FRAXA Research Foundation grant in 2012 to study certain drug effects on Fragile X mice.
BK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials
Discover the promising new BK channel opener, SPG601, now entering clinical trials for Fragile X syndrome. Learn about its potential to restore synaptic function and address core symptoms.
Read moreSensory Hypersensibility in Fragile X Syndrome and BK Channel Openers
With $366,100 in grants from FRAXA Research Foundation, these investigators at the University of Orleans studied sensory abnormalities in Fragile X mice and test the ability of a class of drugs, BK channel openers, to rescue these abnormalities.
Read more